In Brief: Sanofi Winthrop & Ohmeda
Executive Summary
Sanofi Winthrop & Ohmeda: Companies to copromote Ohmeda's Brevibloc (esmolol HCl injection) in the U.S. under a multi-year deal announced Jan. 3. Sanofi Winthrop will market the short-acting beta-blocker to cardiologists and physicians in intensive and critical care units, while Ohmeda will continue to promote Brevibloc to anesthesia and emergency department clinicians. The drug is indicated for rapid control of heart rate and blood pressure...